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A B S T R A C T
Purpose
To identify preferences for and predictors of prognostic information among patients with incurable
metastatic cancer.
Patients and Methods
One hundred twenty-six metastatic cancer patients seeing 30 oncologists at 12 outpatient clinics in New
South Wales, Australia, participated in the study. Patients were diagnosed with incurable metastatic
disease within 6 weeks to 6 months of recruitment. Patients completed a survey eliciting their
preferences for prognostic information, including type, quantity, mode, and timing of presentation;
anxiety and depression levels; and information and involvement preferences.
Results
More than 95% of patients wanted information about side effects, symptoms, and treatment options.
The majority wanted to know longest survival time with treatment (85%), 5-year survival rates (80%),
and average survival (81%). Words and numbers were preferred over pie charts or graphs. Fifty-nine
percent (59%) wanted to discuss expected survival when first diagnosed with metastatic disease.
Thirty-eight percent and 44% wanted to negotiate when expected survival and dying, respectively, were
discussed. Patients with higher depression scores were more likely to want to know shortest time to live
without treatment (P  .047) and average survival (P  .049). Lower depression levels were significantly
associated with never wanting to discuss expected survival (P  .03). Patients with an expected survival of
years were more likely to want to discuss life expectancy when first diagnosed with metastases (P  .02).
Conclusion
Most metastatic cancer patients want detailed prognostic information but prefer to negotiate the extent,
format, and timing of the information they receive from their oncologists.
J Clin Oncol 22:1721-1730. © 2004 by American Society of Clinical Oncology
INTRODUCTION
Cancer patients in developed countries in-
creasingly express a preference for more de-
tailed information and involvement in deci-
sions about their care.1 Documentation of
high levels of psychological morbidity in
cancer patients has also highlighted the im-
portance of doctor communication when
delivering bad news, discussing prognosis
and negotiating treatment decisions.2
Doctors commonly find these interac-
tions challenging. Issues debated in the liter-
ature include how to determine what the
patient wants to hear, whether to provide
life expectancy (eg, median survival) or
make general comments (eg, “I think your
chances are good”), whether to discuss out-
liers, and how to engender hope.3-8 The best
way of presenting prognostic information to
optimize understanding, psychological ad-
justment, and decision-making is uncertain.
To date, much of the communication liter-
ature has focused on how to break bad news,
and there is little guidance available for cli-
nicians in estimating or communicating
prognosis, particularly in the context of
newly diagnosed metastatic disease.
The literature suggests that cancer pa-
tients frequently misunderstand much of
what they are told,9,10 incorrectly state the
extent of their disease and the goal of treat-
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ment, and overestimate their prognosis.9,11-13 Such misun-
derstandingmay lead patients tomake decisions contrary to
their best interests—for example, choosing futile life-
extending therapy at the expense of quality of life.14
The misunderstanding commonly reported in cancer
patients may be attributed in part to poor communication
by physicians.Most doctors inWestern cultures now report
that they tell their cancer patients the diagnosis;15,16 how-
ever, fewer disclose prognosis, particularly when the prog-
nosis is poor.11,17-19 In an Australian study of initial consul-
tations between oncologists and incurable cancer patients,
most patients were informed of the aim of anticancer treat-
ment (85%) and that the disease was incurable (75%).
However, slightly more than half (58%) were told about
life expectancy, only one third (35%) received a quanti-
tative estimate, and fewer than 10% were given a time
frame of life expectancy.20
Doctors face particular difficulties when discussing life
expectancy with patients with a poor prognosis. Such infor-
mation raises immediate issues for the patient, and the
information required includes much shorter time frames
than the long-range forecasting required in early stage dis-
ease. Considerable inaccuracy in doctors’ predictions of the
survival of individual patients with incurable disease has
also been documented.21,22 Kaplowitz et al4 interviewed
physicians about their communication of prognosis with
metastatic cancer patients. Nearly all respondents stated
that they routinely reveal when the cancer cannot be cured
but experienced tension between providing hope and real-
ism in these situations.
A clear majority of cancer patients report a preference
for detailed information about their disease.23-29 However,
few studies have specifically explored preferences for infor-
mation about prognosis. Lobb et al28 surveyed 100 women
with early stage breast cancer about this issue. More than
90%of the womenwanted information about the probabil-
ity of cure, staging details, and the chance that the treatment
would work. Eighty-seven percent wanted 10-year survival
figures, and 70% wanted average survival figures. The
women emphasized that theway information is presented is
as important as the actual content.
Kaplowitz et al30 reported somewhat different re-
sults. A large majority of their sample of early and late
stage cancer patients wanted a qualitative prognosis (eg,
“Will I die from the disease?”); however, less than half
wanted a quantitative estimate of their prognosis, and
those with a poorer prognosis were less likely to request
this information.
A recent qualitative study by Butow et al3 docu-
mented the views of 17 metastatic breast cancer patients
and 13 health professionals on optimal ways of commu-
nicating prognosis to metastatic cancer patients. The
major issues raised were that patient preferences be elic-
ited on an ongoing basis; that information be presented
clearly when desired; that doctors encourage hopefulness
and a sense of control; and that strategies be used to
ensure patient understanding.
The purpose of the current study was to determine the
preferences of a sample of metastatic cancer patients for
content and format of prognostic information and to ex-
plore predictors of these preferences.
PATIENTS AND METHODS
Sample
All oncologists in New South Wales (n  106), Australia,
were invited to participate. Patients of participating oncologists
attending outpatient clinics, diagnosed with metastatic cancer
within the time frame of 6weeks to 6months, whowere older than
18 years, were English speaking, and who had no psychiatric
illness, were recruited onto the study. The oncologists were asked
to identify consecutive patients who fulfilled the eligibility criteria,
briefly inform them about the study, and gain consent for the
researcher to contact them. The researcher then telephoned or
spoke to patients face-to-face, provided more detail about the
study, and gained verbal consent to participate. Patients were then
mailed a copy of the survey, together with a written consent form
and a stamped addressed return envelope, or they completed the
survey immediately in the clinic. Timing of recruitment was cho-
sen to ensure that patients had time to adjust to their diagnosis, be
exposed to information about their own prognosis, and make any
treatment decisions before being approached to participate, thus
reducing the potential for causing distress while still ensuring
survey completion at a time when the issues explored were salient.
Institutional Review Boards at all participating centers reviewed
and approved the conduct of the study.
Measures
Survey development. A written survey was used to elicit pa-
tient preferences for the content and format of prognostic discus-
sion. To develop the items in the survey, key themes were ab-
stracted from the published literature, an earlier qualitative study
in breast cancer patients3 and analysis of audiotapes of initial
oncology consultations.20,31 Two sex-specific hypothetical scenar-
ios (a woman with metastatic breast cancer and a man with met-
astatic prostate cancer) were developed to provide an objective
focus for patients to answer questions on the presentation of
statistical prognostic information. The instrument was reviewed
by oncologists, health professionals, and members of a consumer
advocacy group andwas piloted among 10patientswithmetastatic
cancer, from one of the study centers. Minor revisions were made
in response to reviewers’ and pilot participants’ feedback.
Demographic details. Patientswere asked their ages, relation-
ship status, occupations, highest educational level achieved, med-
ical or allied health training, language spoken at home, parents’
country of birth, and whether or not they had children and reli-
gious beliefs.
Information and involvement preferences. Participants’ pref-
erences for information and involvement were elicited by using
the seven-item binary “Information” subscale of the Krantz
Health Opinion Survey (  0.74 in this sample).32
Depression and anxiety. Levels of depression and anxiety
were measured by the 14-item Hospital and Anxiety and Depres-
sion Scale (HADS) self-assessment tool devised by Zigmond and
Snaith ( 0.84 and  0.81 in this sample).33-35
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Specific prognostic information desired. Participants indi-
cated their preferences for prognostic information from a list of 15
specific information items (eg, average survival, 5-year survival)
by ticking yes or no and indicated in an open-question format why
they would or would not like to know each item.
Preferred presentation of survival statistics. Participants were
asked to read a short scenario of a patient who had recently
developed metastases (from either prostate cancer or breast can-
cer) before considering six different formats of the same prognos-
tic information that could be given to the patient by the cancer
specialist. Participants indicated on a 5-point Likert scale how easy
eachwas to understand and howmuch they liked each format. The
six formats were (1) words, (2) percentage, (3) fraction, (4)100-
person diagram, (5) pie chart, and (6) survival graph. For example
the “word” format for the patient with breast cancer was, “There is
a good chance that Jane will be alive in 2 years time.” The “per-
centage” format for the same scenario was, “There is a 50% chance
that Jane will be alive in 2 years time.” Patients also indicated their
overall preference for “words,” “numbers,” “both,” or “other,”
and the reason for that preference.
When to discuss prognosis and who should initiate the discus-
sion? Participants were asked to indicate when they would like to
receive information on (1) “treatment goals and options,” (2)
“symptoms of the cancer and side effects of treatment,” (3) “how
long I would be likely to live”, and (4) “issues about dying and
palliative care services.” Options given were (1) “when first told
cancer has spread,” (2) “next few consultations,” (3) “later, on
my request,” (4) “never,” or (5) “unsure.” Patients also indi-
cated for each information item whether they would like the (1)
“specialist to just tell me,” (2) “specialist to check first if I want
to know,”(3) “specialist to tell me only if I ask,” (4) “not to
discuss at all,” or (5) “other.”
Statistical analyses. Preferences were analyzed using descrip-
tive statistics. Demographic, psychological, and disease predictors
of patient preferenceswere explored, using2, analysis of variance,
and logistic regression analyses. These predictors included age,
sex, education level (up to 11 years or 12 years), relationship
status (partnered or not), children (0 ormore), father’s country of
birth (Australia or not), whether English was spoken at home (yes
or no), depression and anxiety scores, information preference
style, type of cancer (breast, colorectal, prostate, or other), time
since diagnosis of first cancer and of metastatic disease, expected
survival (weeks to months, months to years, or years), and type of
treatment (active or supportive care).
Only preferences for which fewer than 80% of the sample
indicated a particular preference were included in predictive anal-
yses (ie, where there was sufficient variability). These included:
preference (yes or no) for information regarding average survival,
chance of living 1 year, shortest time to livewithout treatment, and
longest time to live without treatment; preferences for format of
information (like, dislike, or neutral), including survival graph,
100-person diagram, pie chart, and words; and preferences for the
manner of discussing expected survival and palliative care/dying,
including when (immediately, later, or never) and how the discus-
sion should be initiated (specialist to just tell or tell only if asked/
check first). Predictors that were found to be significant at the 0.25
level in univariate analyses were entered into binary and multino-
mial logistic regressions as appropriate.36 Because anxiety and
depression scores were highly correlated (Pearson’s correlation
0.57; P  .01) only one of these scores (the more significant on
univariate analysis) was entered into multivariate analyses.
RESULTS
Patients were recruited from 12 clinics inNew SouthWales,
Australia, by 30 participating oncologists, of whom 19 were
medical oncologists and 11 were radiation oncologists.
Eighteen of 106 invited oncologists actively refused to par-
ticipate (primarily because of insufficient time or that they
were no longer practicing in oncology), and 58 did not
respond. Data were available on oncologists who refused
and accepted. No differences were found in age, years in
practice, specialty (medical or radiation oncology), and
number of total cancer and metastatic cancer patients seen
per year between these groups. Nevertheless, it is possible
that the resulting patient sample has some bias, in that they
were accrued from a small (though apparently representa-
tive) group of oncologists.
Of the 218 patients approached to participate, 10 were
ineligible, and 22 refused. Of 186 patients who agreed to
participate, 126 completed the survey. The most common
reason cited for not completing the surveywas ill health. No
significant differences were found between those who com-
pleted and those who did not complete the survey on the
variables of age (F2,194 0.180; P .672), sex (
21 0.294;
P .588), clinic where recruited (metropolitan or nonmet-
ropolitan; 21  2.540; P  .111), type of cancer (24 
4.429; P  .362), nor time since diagnosis of metastatic
disease (F2,192 0.008; P .930).
Of the 126 patients who completed the survey, 54%
were male; 25% had breast cancer, 18% had colorectal
cancer, 15% had prostate cancer, 10% had lung cancer, and
30% had other cancer types. Themean time since diagnosis
of metastases was 13 weeks (range, 1 to 39 weeks; standard
deviation [SD], 8.7 weeks). The majority had an expected
survival estimated by their oncologist of months (42%), or
years (42%) and were receiving anticancer treatment with
either systemic therapy or radiotherapy (92%; Table 1).
Information and Involvement Preferences
The average score on the Krantz Health Opinion
Survey: Information Preferences Subscale was 3.9 (SD,
2.15), which is in the medium score range, indicating
that, overall, participants did not have either a particu-
larly high or low desire to ask questions or to be informed
about medical decisions.32
Anxiety and Depression
Scores on the HADS show that the majority of partici-
pants fell into the“normal”or“noncase” range (scores0-7) for
both anxiety (67%) and depression (74%). Twenty-three per-
cent and 19%, respectively, fell into the “possible case” range
(scores 8-10) for anxiety and depression respectively. Ten per-
cent and 7% of patients fell into the “probable case” range
(scores 11-21) for anxiety or depression, respectively.33
Patients’ Prognosis-Communication Preferences
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Prognostic Information Desired
Almost all patients wanted information that related to
treatment, for example treatment options (98%), common
side effects of treatment (99%), information relating to the
goals of treatment such as the chance that the treatment will
improve symptoms (96%). Most patients also wanted to
know about uncommon treatment side effects (91%), and
both common (97%) and uncommon symptoms of the
cancer (88%; Table 2).
More specifically, 91% of participants wanted to know
about less common symptoms and treatment side effects
(ie, those that could occur in 10 of 100 patients). More than
one third (38%) wanted information about very rare symp-
toms or side effects (ie, those that could occur in 5 of 1,000
patients), and 36% wanted to know about those that oc-
curred in 1 of 1,000 patients. The most common reason
cited by patients for wanting to know details of uncommon
side effects and symptoms was to enable them to make
treatment decisions and prepare for the future.
Themajority also desired information items about sur-
vival duration. Information that could be perceived asmore
positive—for example, “the chance of living 5 years” (80%),
“the average length of time I would be likely to live” (81%)
and “the longest survival without treatment” (76%) was
desired by slightly more patients than less positive informa-
tion—for example, 1-year survival rates (65%) and the
shortest survival without treatment (72%).
The most common reason patients cited for prefer-
ring not to receive survival information was that this
information would not be useful because it could not be
accurately predicted.
Preference for Format
Words and numbers were preferred over visual presen-
tations such as pie charts or graphs and were deemed easier
to understand (See Table 3). Ratings of preference and ease
of understanding for each format were found to be signifi-
cantly and positively correlated at the P  .01 significance
level (words: R 0.6; percentages: R 0.6; fractions: R
0.5; 100 persondiagram:R 0.5; pie chart:R 0.5; survival
graph: R 0.6).
Patients commented: “Words and numbers seemmore
optimistic and less clinical”; “I think words are not as
harsh—even though you have to face up to the inevitable—
words don’t seem to be so final; [they] give hope!”; “Charts
and numbers are too dogmatic; they do not necessarily
relate to my specific problem.”
When to Discuss and Who Should Initiate
the Discussion
The majority indicated that they wanted to discuss
treatment goals and options (84%), and symptoms and side
effects (81%) when “first diagnosed” with metastatic dis-
ease and also for the specialist to “just tell them” this infor-
mation (83% and 81%, respectively). Fewer wanted to be
told how long they had to live (59%) when first diagnosed,
and for the specialist to “just tell them” this (53%). One
third wanted to discuss issues about dying and palliative
care when first diagnosed with metastatic disease, and one
third wanted to discuss these issues later; 45% wanted the
Table 1. Patient Characteristics
Demographic % of Patients
Age, years
Mean 62.6
SD 11.7
Range 34-82
Sex
Male 54
Female 46
Area
Metropolitan 85
Non-metropolitan 15
Relationship status
Married/de facto 64
Other 36
Occupation
Professional 18
Non-professional 82
Medical/allied health training 6
Education level
University entrance level and above 53
Less than university entrance level 47
Language spoken at home
English 92
Other 8
Ethnicity
Anglo-Saxon 86
Non–Anglo-Saxon 14
Children 84
Religious belief 88
Primary cancer
Breast 25
Colorectal 18
Prostate 16
Lung 10
Melanoma 5
Unknown primary 4
Ovarian 2
Other 20
Time since diagnosis of primary, months
Mean 36
Range 1-349
Time since diagnosis of metastases, weeks
Mean 13
Range 1-39
Estimated survival
Weeks 3
Months 42
Months to years 13
Years 42
Treatment
Anti-cancer (systemic or local) 92
Non–anti-cancer/supportive care 8
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specialist to raise these issues. A minority of patients (11%)
preferred never to discuss dying and palliative care or were
unsure (10%). However, many patients wanted the special-
ist to check first if they wanted to discuss expected survival
(17%) and dying and palliative care (20%) or indicated that
they only wanted the information if they asked (21% for
survival and 24% for dying and palliative care, respectively;
Table 4).
Predictors of Patient Preferences
Several key variables emerged in multivariate analyses
as predictors of preference for content, format, and when
and how to initiate discussions of prognosis.
Content. Patients with higher depression scores were
more likely to want to know average survival (P .049) and
the shortest time to live without treatment (P  .047).
Those with an expected survival of weeks or months (as
opposed to months to years or years; P  .047) and those
who had higher HADS anxiety scores (P  .02) were less
likely to want to know the chance of living 1 year. Those
with higher scores on the HADS anxiety and Krantz in-
volvement preference scales were more likely to want to
know the longest time to live without treatment (P .009
and P .04, respectively; Table 5).
Format. In terms of preference for format, partici-
pants of Anglo-Saxon background weremore likely to want
words (P .005). Older patients were more likely to prefer
the 100-person diagram (P .03). Those with higher scores
on the Krantz involvement preference scale were more
likely to dislike the pie chart (P .005), whereas those who
had more than 12 years of school education were more
likely to prefer this format (P .02; Table 6).
When and how to initiate prognostic discussions. Due to
the occurrence of singularity in the Hessian matrix in the
multinomial logistic regression of “when to discuss how long
to live,” two separate binary logistic regressions were executed
with outcome variables coded as “immediately/later or never”
and “immediately or later/never.” Patients who were less de-
pressed were more likely to want to never (as opposed to
Table 2. Specific Prognostic Information Desired
Type of Prognostic Information
Want, % of
Patients
Do Not Want, % of
Patients % Responding
Common side effects of treatment 99 1 96
Treatment options 98 2 97
Common symptoms from the cancer 97 3 96
Chance that the treatment will improve symptoms 96 4 96
Uncommon symptoms from the cancer 88 12 94
Chances of treatment shrinking the cancer 95 5 98
Likely time you will be without symptoms 92 8 93
Factors which make my prognosis better or worse than average 92 8 94
Uncommon treatment side effects 91 9 94
The longest time you might live, if treatment worked as well as could be expected 85 15 94
Average length of time you would be likely to live 81 19 95
The chance of living 5 years 80 20 92
Chance of living 1 year 65 35 91
The longest time you might live without treatment 76 24 94
The shortest time you might live without treatment 72 28 94
Table 3. Format of Statistics: Rated Ease of Understanding and Preference
% of Patients
Words Percentages Fraction 100-Person Diagram Pie Chart Graph
Ease of understanding
Easy 67 65 69 56 60 40
Difficult 11 10 12 23 10 31
Neutral 14 14 11 8 18 13
Responded 92 89 89 87 88 83
Preference
Like 47 42 40 25 28 21
Dislike 17 17 28 48 48 53
Neutral 17 18 11 8 4 8
Responded 81 77 79 81 80 82
Patients’ Prognosis-Communication Preferences
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immediately or later) discuss how long they had to live (P
.03). Patients who were expected to survive for years (as op-
posed toweeks tomonthsormonths toyears)weremore likely
to want to discuss how long to live when first diagnosed with
metastatic disease (P .02).
With regard to when to discuss palliative care and
dying, a mulitinomial regression was undertaken. Patients
who had children were more likely to want to discuss these
issues in later consultations than when first diagnosed with
metastases or never (P .02; Table 7).
Patients with colorectal cancer (P .02) or prostate
cancer (P .04; as opposed to those with breast cancer or
other type of cancer) were more likely to want to have
prognostic discussions negotiated as opposed to the spe-
cialist “just telling,” them, and among these patients,
there was a strong trend for younger patients to prefer
this (P  .057). Colorectal cancer patients were also
more likely to want to negotiate the discussion of issues
about dying and palliative care (P  .02; Table 7). No
other predictors were identified
DISCUSSION
In this survey of cancer patients with metastatic cancer, we
found that the majority want detailed prognostic informa-
tion. These findings support earlier studies of general infor-
mation needs in cancer patients,23,24,26-29 our earlier quali-
tative study of the prognostic information needs of patients
with metastatic breast cancer patients,3 and our quantita-
tive study of early stage breast cancer patients.28 However,
our findings contrast with those of Kaplowitz et al,30 who
found that, although a large majority of patients wanted
prognostic estimates using verbal descriptors, less than half
wanted a quantitative estimate of survival. Although more
patients in our sample wanted the more positive informa-
tion (that implied either a long time frame or pertained to
Table 4. Negotiation of Prognostic Discussion
Type of Prognostic Information
% of Patients
Treatment
Goals and
Options
Symptoms and
Treatment Side
Effects
Likely Duration
of Survival
Dying or Palliative
Care Services
When to discuss
When first told cancer has spread 84 81 59 33
Next few consultations 21 23 15 19
Later, upon my request 9 9 22 33
Never 1 1 12 11
Unsure 1 2 7 10
Responded 99 98 91 87
Who to initiate discussion
Specialist just to tell 83 81 53 45
Specialist to check first if want to know 15 14 17 20
Specialist to tell only if I ask 3 6 21 24
Not to discuss at all 0 0 9 2
Other 1 1 1 2
Responded 97 97 87 85
NOTE. Respondents were given the option to select more than one item.
Table 5. Results of Multivariate Analysis: Preference for Content of Prognostic Information
Outcome Significant Variables OR P 95% CI
Average survival Depression 1.118 .049 1.001 to 1.382
Chance of living 1 year† Expected survival (weeks/months) 0.115 .047 0.014 to 0.973
Anxiety 1.170 .02 1.023 to 1.337
Shortest time to live without treatment‡ Depression 1.207 .047 1.014 to 1.437
Longest time to live without treatment§ Anxiety 1.224 .009 1.012 to 1.590
Involvement preferences 1.268 .04 1.053 to 1.423
NOTE. Variables entered were those found to be significant at the 0.25 level in univariate analyses. Only outcomes found to have significant results in
multivariate analyses are presented.
Abbreviation: OR, odds ratio.
Variables entered: expected survival, depression, involvement preferences.
†Variables entered: age, expected survival, time since first cancer diagnosis, cancer, anxiety.
‡Variables entered: children, language, depression, involvement preferences, cancer, time since diagnosis of metastases, expected survival.
§Variables entered: age, children, relationship status, time since first diagnosis, cancer, involvement preferences, anxiety.
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positive outliers), more than 65% also wanted the less pos-
itive information (shortest survival without treatment and
1-year survival rates). The most common reasons cited for
wanting the latter were that it would allow patients to pre-
pare themselves and their families for the future and would
assist with decision making and life planning, which reflect
the findings of our previous qualitative study.3 These results
should reassure those Australian oncologists and members
of the healthcare team who fear conveying poor prognostic
information to their patients.
Although patients clearly want prognostic informa-
tion, it is not always easy for doctors to accurately estimate
prognosis. MacKillop and Quirt21 determined the accuracy
of oncologists’ predictions of survival time of cancer pa-
tients. Although these oncologists’ estimates of the proba-
bility of cure were accurate, and their predictions of the
overall expected survival of incurable patients were well
calibrated, their predictions for individual patients were
imprecise. If the oncology community is to adequately re-
spond to patient information needs, we will need to devise
ways of improving both the accuracy of prognostic esti-
mates and ways to communicate medical uncertainty to
patients. The latter may be achieved by devising creative
ways to depict a range of values, such as pie and survival
graphs with shaded areas around the line to indicate 95%
CIs. Simply discussing the methods by which prognoses are
formulated and acknowledging the uncertainty inherent in
that processmay be sufficient.However, there is a paucity of
evidence regarding the impact of acknowledging medical
uncertainty on patient outcomes; two studies outside on-
cology have produced conflicting results. (One found such
acknowledgment led to a reduction in patient confidence,
the other an increase in patient satisfaction, although there
was considerable variability in responses.) 37,38
However, although prognosis is often equated with
survival time, patients in this study indicated a desire for
broader information about their likely futures, including
how the illness may affect their daily lives, with less empha-
sis placed on survival estimates. More than one third of
patients in this surveywanted information about symptoms
and side effects occurring in fewer than 5 of 1,000 patients,
suggesting that these quality-of-life issues are very impor-
tant to patients.
Furthermore, approixmately 60% of the patients sur-
veyed wanted information about expected survival when
first informed of their metastatic diagnosis, with one half
Table 6. Results of Multivariate Analysis: Preference for Format of Prognostic Statistics
Format Significant Variables OR P 95% CI
Words Parent’s ethnicity (Anglo-Saxon) 0.167 .005 0.048 to 0.584
100-person diagram† Age 1.04 .03 1.003 to 1.074
Pie chart‡ Involvement preferences 1.431 .005 0.108 to 0.853
Education level ( 12 years) 1.431 .02 1.114 to 1.840
NOTE. Variables entered were those found to be significant at the 0.25 level in univariate analyses. Only outcomes found to have significant results in
multivariate analyses are presented.
Abbreviation: OR, odds ratio.
Variables entered: age, parent’s country of birth, treatment.
†Variables entered: age, education level.
‡Variables entered: age, relationship status, education level, parent’s country of birth, cancer, involvement preferences.
Table 7. Results of Multivariate Analysis: Preference for When and How to Initiate Prognostic Discussions
Outcome Significant variables OR P 95% CI
When to discuss how long to live (immediately v later or never) Expected survival (years) 6.656 .02 1.311 to 33.781
When to discuss how long to live (immediately/later v never)† Depression 0.771 .03 0.612 to 0.971
How to initiate: how long to live (Specialist to just tell v check first)‡ Cancer (colorectal) 7.303 .02 1.384 to 38.543
Cancer (prostate) 6.394 .04 1.142 to 35.814
When to discuss dying and palliative care (immediately v later v never)§ Children (yes) 0.124 .02 2.147E-02 to 0.712
How to initiate discussion of dying or palliative care (Specialist to just
tell v check first)
Cancer (colorectal) 5.353 .02 1.459 to 23.560
NOTE. Variables entered were those found to be significant at the 0.25 level in univariate analyses. Only outcomes found to have significant results in
multivariate analyses are presented.
Abbreviation: OR, odds ratio.
Variables entered: gender, expected survival, treatment.
†Variables entered: expected survival, involvement preferences, depression, time since diagnosis of metastatic disease, treatment.
‡Variables entered: age, gender, education level, expected survival, cancer, involvement preferences.
§Variables entered: expected survival, cancer, children, time since first diagnosis and depression.
Variables entered: age, gender, children, education level, expected survival, cancer, depression, involvement preferences.
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preferring either that the doctor “just to tell” him or her,
rather than waiting for the patient to ask or negotiating
what and when to tell. However, given that approximately
40% of patients indicated they wanted both information
about life expectancy and dying and palliative care issues
only if they asked for it or after negotiation, there remains a
considerable challenge for the oncologist in knowing how
to tailor information to the individual patient. Many doc-
tors rely on their intuition to guide them in this; however,
several studies have shown that doctors are not accurate in
guessing patients’ preferences for information and involve-
ment.39,40 Open negotiation seems the preferred course.
Given that the majority in our study wanted prognostic
information as soon as metastatic disease was diagnosed, it
may be helpful to begin negotiating what prognostic infor-
mation to disclose and the preferred way to do so from the
first consultation. Interestingly, patients indicated that they
might prefer prognostic information discussed over several
consultations, suggesting (understandably) that it may take
some time for them to ready themselves to hear, under-
stand, and adjust to this information—particularly for pa-
tients with shorter expected survival.
With regard to presenting statistical information, pa-
tients generally preferred words and numerical descriptors
to graphical representations. Unlike the findings of
Kaplowitz et al,30 patients did not report a clear preference
for either the perceived qualitative softness of words or the
greater precision of numbers. Both were equally endorsed,
with the majority of patients reporting a preference for
both. One subgroup (participants of non–Anglo Saxon back-
ground),however,was significantlymore likely toprefernum-
bers to words. Perhaps these patients were struggling with
English-languagedeficiencies and foundnumbersmoreacces-
sible. In this group particularly, it would be important to back
upwordswithnumbers or graphic representationswherepos-
sible. Ratings for preference and ease of understanding of each
format were found to be significantly associated; however,
these correlations were not very high, suggesting that factors
other than ease of understanding are influencing patients’
overall preferences for format of statistics.
The general dislike of graphic representations is con-
cerning, given their growing inclusion in decision aids de-
signed to improve patient understanding and involvement
in treatment decisions. However, many patients in this
study reported that they found the graphical representa-
tions the most difficult to understand, as well as cold, clin-
ical, and confrontational. That many patients chose not to
complete these questions could also be indicative of this.
Are we doing harm in showing these to patients, or will they
help patients over the long term to understand and come to
terms with the information they represent? Further re-
search is needed to clarify these issues.
Depression and anxiety were the strongest predictors
overall for preferences for prognostic information. Patients
with higher depression or anxiety scores weremore likely to
want to discuss expected survival andwanted to knowmore
prognostic information, particularly about more negative
outcomes, such as death. Perhaps these patients feel more
vulnerable to and worried about death. Notably, the differ-
ence in depression and anxiety scores between those who
wanted prognostic facts and thosewho did notwas small, so
it would be difficult (and inappropriate) to use this as the
deciding factor in determining whether or not to disclose
prognosis. However, these results at least highlight the need
for an awareness of and ability to address patients’ cogni-
tions and emotions when discussing prognosis.
Patients with colorectal or prostate cancer were more
likely to prefer their specialist tell them their expected sur-
vival and issues regarding dying and palliative care only
after negotiation. It is possible that this group is less politi-
cized than patients with other cancers. Breast cancer lobby
groups are now very active in Australia, and individual
patients with this condition may be more likely to be in-
formed and to have an expectation that prognostic infor-
mation is provided to allow informed decision-making.
Limitations of the Study and Summary
An important issue in surveys of this nature that at-
tempt to describe the prevalence of views is the potential
bias in the sample. Although 30 oncologists took part in this
study, 106 were invited to participate. It is possible that the
participating oncologists were biased by their interest in
communication issues. This interest may influence their
interaction with their patients, which may have subse-
quently biased the patient responses in this study.When we
compared those oncologists who actively refused to partic-
ipate with those who accepted, no demographic or practice
differences were observed. However, no data were available
on oncologists who did not respond at all. Furthermore,
more subtle differences (such as interest in communica-
tion) that we did not measure may have differentiated par-
ticipants from nonparticipants, so this remains a concern.
Oncologists were asked to invite consecutive patients
who fulfilled the eligibility criteria; however, not all oncolo-
gists may have complied with this instruction. They may
have invited patients who felt more comfortable with their
diagnosis or who were less symptomatic, although the on-
cologists did not report using these criteria to determine
participation. The majority of patients in this sample were
on “anticancer” therapy. However, this is characteristic of
outpatient oncology patients with a recent diagnosis of
metastases.20,21,41-43 In Australia, there is no obstacle to
patients’ receiving palliative or hospice care while receiving
anticancer treatment, unlike the situation in the United
States. We were unable to gather data on nonparticipants
regarding expected survival or treatment received, because
of concerns expressed by the ethical review boards to which
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the protocol was submitted. Therefore, we were unable to
assess bias in the sample on these variables.
It is possible that participants were more comfortable
with addressing prognostic issues than nonparticipants.
There was a low prevalence of probable cases of anxiety and
depression in the sample; however, these were similar to
levels of anxiety and depression reported in a sample of 159
patients with advanced disease recruited in a large English
study with only a 4% refusal rate,34 which suggests that we
did not have a particularly psychologically resilient sample.
Patients were invited to participate between 6 weeks
and 6 months since their diagnosis of metastatic cancer. As
stated earlier, this timing was chosen on ethical grounds to
avoid distress in newly diagnosed patients and to allow
patients time to reflect on the whole experience when pro-
viding responses. However, it is possible that participants’
responses were influenced by the discussions they had with
their oncologists about prognosis during this time period
and that these responses would have been different had the
patients been surveyed when they were first diagnosed. We
have no data on participants’ actual prognostic discussions.
Time since diagnosis was not significantly associated with
any of the preferences elicited in the current study, suggest-
ing that preferences are stable at least after 6weeks. Further-
more, nearly 50% in our sample stated that they preferred
expected survival to be discussed some time after their
diagnosis of metastases, suggesting that the survey timing
was appropriate. We are following up with patients 6
months later to determine whether their situation and pref-
erences have changed; however, these data are not yet com-
plete. Future research might usefully explore differences
between immediate and later preferences.
Participants were predominantly (85%) of Anglo-
Saxon background, andmost (91%) spoke English at home;
they are, therefore, not representative of Australia’s cultur-
ally diverse population. Many cultures have been found to
have particular communication preferences and needs,44-48
and future studies could usefully explore their specific pref-
erences for prognostic information.
It still remains uncertainwho the patients arewhowant
particular information at particular times. Although some
predictors of preferences in multivariate models were iden-
tified, none were found to explain a large amount of the
variance, suggesting that there are factors other than those
examined here that influence patient prognostic informa-
tion preferences. A larger sample size would have perhaps
allowed for detection of more predictors.
Nonetheless, this study has provided an important step
toward improving the discussion of prognosis with meta-
static cancer patients, which is a difficult and sensitive pro-
cess for both clinicians and patients. We have specifically
identified what these patients want to be told and how and
when they want to hear it.
It seems from these and other data that prognostic
communication is highly complex and that interventions
are needed to facilitate this process. One possible interven-
tion is a question-prompt list; these have been found by our
group to significantly increase patient question-asking
about prognosis while significantly decreasing anxiety levels
if endorsed by the clinician.49-51
■ ■ ■
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